LyncBio Therapeutics Co., Ltd.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
LyncBio Therapeutics Co., Ltd. - overview
Established
2023
Location
Shanghai, Pudong New District, China
Primary Industry
Pharmaceuticals
About
Based in China, LyncBio Therapeutics Co. , Ltd. specializes in developing innovative Antibody-Drug Conjugates (ADCs) aimed at improving targeted cancer therapies and addressing unmet medical needs in oncology and other diseases. LyncBio Therapeutics Co.
, Ltd. focuses on the research and development of next-generation ADC technologies. Founded in 2023 and headquartered in Shanghai, China, the company has successfully conducted 2 funding deals, with its latest round being a CNY 100. 000 mn investment from Panlin Capital and Xingze Capital.
This funding brings the total amount raised to CNY 100. 000 mn. LyncBio specializes in the development and innovation of next-generation Antibody-Drug Conjugates (ADCs), designed to enhance targeted cancer therapies. Their offerings include a suite of multifunctional carriers, conjugates, linkers, and drug payloads, enabling precise targeting of cancer cells via single-target and dual-target ADC designs.
The company utilizes advanced methodologies and proprietary technology platforms to address global patient needs in oncology, inflammatory bowel disease, and multiple sclerosis, aiming for broad international market reach. LyncBio generates revenue through strategic partnerships and collaborations with healthcare providers and research institutions seeking advanced therapeutic solutions. The company engages in business-to-business transactions, offering ADC technologies and related services to pharmaceutical companies and clinical research organizations. Revenue is derived from contractual agreements, licensing fees, and milestone payments associated with their proprietary technologies, underscoring the value of their innovative ADC solutions in addressing significant health challenges.
LyncBio Therapeutics Co. , Ltd. plans to expand its product portfolio with new ADC innovations in the coming years. The company is targeting markets in North America and Europe for expansion by 2025, leveraging its recent CNY 100.
000 mn funding to support these initiatives. This funding will facilitate the development of new products and enhance market entry strategies into these significant regions.
Current Investors
Panlin Capital, Xingze Capital
Primary Industry
Pharmaceuticals
Sub Industries
Molecular Science, Genetics & Gene Therapy, Biopharmaceuticals, Pharmaceutical Research & Development
Website
www.lyncbio.com
Company Stage
Angel & Seed
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.